{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:23:05Z","timestamp":1794428585279,"version":"4.9.1"},"reference-count":174,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T00:00:00Z","timestamp":1553040000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"crossref","award":["HI15C0972"],"award-info":[{"award-number":["HI15C0972"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2019R1A2C2006475"],"award-info":[{"award-number":["2019R1A2C2006475"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"name":"MRC grant from National Research Foundation of Korea","award":["2018R1A5A2020732"],"award-info":[{"award-number":["2018R1A5A2020732"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s12272-019-01143-y","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T11:04:08Z","timestamp":1553079848000},"page":"591-606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Natural killer cells as a promising therapeutic target for cancer immunotherapy"],"prefix":"10.1007","volume":"42","author":[{"given":"Nayoung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Seon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5729-6581","authenticated-orcid":false,"given":"Hun Sik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,20]]},"reference":[{"key":"1143_CR1","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","volume":"9","author":"AM Abel","year":"2018","unstructured":"Abel AM, Yang C, Thakar MS, Malarkannan S (2018) Natural killer cells: development, maturation, and clinical utilization. Front Immunol 9:1869","journal-title":"Front Immunol"},{"key":"1143_CR2","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK (2016) Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44:989\u20131004","journal-title":"Immunity"},{"issue":"1731\u20131743","key":"1143_CR3","first-page":"e13","volume":"175","author":"P Andre","year":"2018","unstructured":"Andre P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Blery M, Bonnafous C, Gauthier L, Morel A, Rossi B, Remark R, Breso V, Bonnet E, Habif G, Guia S, Lalanne AI, Hoffmann C, Lantz O, Fayette J, Boyer-Chammard A, Zerbib R, Dodion P, Ghadially H, Jure-Kunkel M, Morel Y, Herbst R, Narni-Mancinelli E, Cohen RB, Vivier E (2018) Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 175(1731\u20131743):e13","journal-title":"Cell"},{"key":"1143_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.immuni.2006.06.013","volume":"25","author":"N Anfossi","year":"2006","unstructured":"Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton D, Romagne F, Ugolini S, Vivier E (2006) Human NK cell education by inhibitory receptors for MHC class I. Immunity 25:331\u2013342","journal-title":"Immunity"},{"key":"1143_CR5","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1245\/s10434-018-6691-3","volume":"25","author":"L Angka","year":"2018","unstructured":"Angka L, Martel AB, Kilgour M, Jeong A, Sadiq M, De Souza CT, Baker L, Kennedy MA, Kekre N, Auer RC (2018) Natural killer cell IFNgamma secretion is profoundly suppressed following colorectal cancer surgery. Ann Surg Oncol 25:3747\u20133754","journal-title":"Ann Surg Oncol"},{"key":"1143_CR6","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1056\/NEJM199810223391702","volume":"339","author":"F Aversa","year":"1998","unstructured":"Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, Ruggeri L, Barbabietola G, Aristei C, Latini P, Reisner Y, Martelli MF (1998) Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 339:1186\u20131193","journal-title":"N Engl J Med"},{"key":"1143_CR7","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","volume":"123","author":"V Bachanova","year":"2014","unstructured":"Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, Mckenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lewis D, Hippen K, Mcglave P, Weisdorf DJ, Blazar BR, Miller JS (2014) Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123:3855\u20133863","journal-title":"Blood"},{"key":"1143_CR8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00262-017-2100-1","volume":"67","author":"V Bachanova","year":"2018","unstructured":"Bachanova V, Sarhan D, Defor TE, Cooley S, Panoskaltsis-Mortari A, Blazar BR, Curtsinger JM, Burns L, Weisdorf DJ, Miller JS (2018) Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother 67:483\u2013494","journal-title":"Cancer Immunol Immunother"},{"key":"1143_CR9","doi-asserted-by":"publisher","first-page":"20847","DOI":"10.1073\/pnas.0906481106","volume":"106","author":"M Balsamo","year":"2009","unstructured":"Balsamo M, Scordamaglia F, Pietra G, Manzini C, Cantoni C, Boitano M, Queirolo P, Vermi W, Facchetti F, Moretta A, Moretta L, Mingari MC, Vitale M (2009) Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci USA 106:20847\u201320852","journal-title":"Proc Natl Acad Sci USA"},{"key":"1143_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nrc3958","volume":"15","author":"HE Barker","year":"2015","unstructured":"Barker HE, Paget JT, Khan AA, Harrington KJ (2015) The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer 15:409\u2013425","journal-title":"Nat Rev Cancer"},{"key":"1143_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1006\/clin.1994.1055","volume":"71","author":"CN Baxevanis","year":"1994","unstructured":"Baxevanis CN, Papilas K, Dedoussis GV, Pavlis T, Papamichail M (1994) Abnormal cytokine serum levels correlate with impaired cellular immune responses after surgery. Clin Immunol Immunopathol 71:82\u201388","journal-title":"Clin Immunol Immunopathol"},{"key":"1143_CR12","doi-asserted-by":"publisher","first-page":"72961","DOI":"10.18632\/oncotarget.12150","volume":"7","author":"A Beldi-Ferchiou","year":"2016","unstructured":"Beldi-Ferchiou A, Lambert M, Dogniaux S, Vely F, Vivier E, Olive D, Dupuy S, Levasseur F, Zucman D, Lebbe C, Sene D, Hivroz C, Caillat-Zucman S (2016) PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget 7:72961\u201372977","journal-title":"Oncotarget"},{"key":"1143_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jaut.2014.10.002","volume":"56","author":"CJ Bell","year":"2015","unstructured":"Bell CJ, Sun Y, Nowak UM, Clark J, Howlett S, Pekalski ML, Yang X, Ast O, Waldhauer I, Freimoser-Grundschober A, Moessner E, Umana P, Klein C, Hosse RJ, Wicker LS, Peterson LB (2015) Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. J Autoimmun 56:66\u201380","journal-title":"J Autoimmun"},{"key":"1143_CR14","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-15-0304","volume":"21","author":"DM Benson Jr","year":"2015","unstructured":"Benson DM Jr, Cohen AD, Jagannath S, Munshi NC, Spitzer G, Hofmeister CC, Efebera YA, Andre P, Zerbib R, Caligiuri MA (2015) A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed\/refractory multiple myeloma. Clin Cancer Res 21:4055\u20134061","journal-title":"Clin Cancer Res"},{"key":"1143_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1084\/jem.20050449","volume":"202","author":"C Bloch-Queyrat","year":"2005","unstructured":"Bloch-Queyrat C, Fondaneche MC, Chen R, Yin L, Relouzat F, Veillette A, Fischer A, Latour S (2005) Regulation of natural cytotoxicity by the adaptor SAP and the Src-related kinase Fyn. J Exp Med 202:181\u2013192","journal-title":"J Exp Med"},{"key":"1143_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1084\/jem.20030788","volume":"198","author":"C Bottino","year":"2003","unstructured":"Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, Cantoni C, Grassi J, Marcenaro S, Reymond N, Vitale M, Moretta L, Lopez M, Moretta A (2003) Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 198:557\u2013567","journal-title":"J Exp Med"},{"key":"1143_CR17","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1084\/jem.20090681","volume":"206","author":"CS Brandt","year":"2009","unstructured":"Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C, Moretta A, West R, Xu W, Vivier E, Levin SD (2009) The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 206:1495\u20131503","journal-title":"J Exp Med"},{"key":"1143_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1600-065X.2006.00457.x","volume":"214","author":"YT Bryceson","year":"2006","unstructured":"Bryceson YT, March ME, Ljunggren HG, Long EO (2006a) Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 214:73\u201391","journal-title":"Immunol Rev"},{"key":"1143_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood-2005-04-1351","volume":"107","author":"YT Bryceson","year":"2006","unstructured":"Bryceson YT, March ME, Ljunggren HG, Long EO (2006b) Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107:159\u2013166","journal-title":"Blood"},{"key":"1143_CR20","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1182\/blood-2009-01-201632","volume":"114","author":"YT Bryceson","year":"2009","unstructured":"Bryceson YT, Ljunggren HG, Long EO (2009) Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood 114:2657\u20132666","journal-title":"Blood"},{"key":"1143_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1074-7613(00)80300-3","volume":"4","author":"DN Burshtyn","year":"1996","unstructured":"Burshtyn DN, Scharenberg AM, Wagtmann N, Rajagopalan S, Berrada K, Yi T, Kinet JP, Long EO (1996) Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity 4:77\u201385","journal-title":"Immunity"},{"key":"1143_CR22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","volume":"112","author":"MA Caligiuri","year":"2008","unstructured":"Caligiuri MA (2008) Human natural killer cells. Blood 112:461\u2013469","journal-title":"Blood"},{"key":"1143_CR23","doi-asserted-by":"publisher","first-page":"e1017701","DOI":"10.1080\/2162402X.2015.1017701","volume":"4","author":"J Cany","year":"2015","unstructured":"Cany J, Van Der Waart AB, Spanholtz J, Tordoir M, Jansen JH, Van Der Voort R, Schaap NM, Dolstra H (2015) Combined IL-15 and IL-12 drives the generation of CD34(+)-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer. Oncoimmunology 4:e1017701","journal-title":"Oncoimmunology"},{"key":"1143_CR24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fimmu.2016.00152","volume":"7","author":"S Carotta","year":"2016","unstructured":"Carotta S (2016) Targeting NK cells for anticancer immunotherapy: clinical and preclinical approaches. Front Immunol 7:152","journal-title":"Front Immunol"},{"key":"1143_CR25","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.4049\/jimmunol.0802845","volume":"182","author":"R Castriconi","year":"2009","unstructured":"Castriconi R, Daga A, Dondero A, Zona G, Poliani PL, Melotti A, Griffero F, Marubbi D, Spaziante R, Bellora F, Moretta L, Moretta A, Corte G, Bottino C (2009) NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol 182:3530\u20133539","journal-title":"J Immunol"},{"key":"1143_CR26","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.molmed.2017.03.002","volume":"23","author":"ZL Chang","year":"2017","unstructured":"Chang ZL, Chen YY (2017) CARs: synthetic immunoreceptors for cancer therapy and beyond. Trends Mol Med 23:430\u2013450","journal-title":"Trends Mol Med"},{"key":"1143_CR27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cell.2012.03.009","volume":"149","author":"J Chen","year":"2012","unstructured":"Chen J, Mckay RM, Parada LF (2012) Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell 149:36\u201347","journal-title":"Cell"},{"key":"1143_CR28","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrd4506","volume":"14","author":"RW Childs","year":"2015","unstructured":"Childs RW, Carlsten M (2015) Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nat Rev Drug Discov 14:487\u2013498","journal-title":"Nat Rev Drug Discov"},{"key":"1143_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.smim.2017.08.003","volume":"31","author":"L Chiossone","year":"2017","unstructured":"Chiossone L, Vienne M, Kerdiles YM, Vivier E (2017) Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more. Semin Immunol 31:55\u201363","journal-title":"Semin Immunol"},{"key":"1143_CR30","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41577-018-0061-z","volume":"18","author":"L Chiossone","year":"2018","unstructured":"Chiossone L, Dumas PY, Vienne M, Vivier E (2018) Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol 18:671\u2013688","journal-title":"Nat Rev Immunol"},{"key":"1143_CR31","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.3390\/ijms19092771","volume":"19","author":"YJ Cho","year":"2018","unstructured":"Cho YJ, Lee HH, Kang H, Cho H (2018) Cytokine-modulated natural killer cells differentially regulate the activity of the hepatitis C virus. Int J Mol Sci 19:2771","journal-title":"Int J Mol Sci"},{"key":"1143_CR32","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.bbmt.2014.01.031","volume":"20","author":"I Choi","year":"2014","unstructured":"Choi I, Yoon SR, Park SY, Kim H, Jung SJ, Jang YJ, Kang M, Yeom YI, Lee JL, Kim DY, Lee YS, Kang YA, Jeon M, Seol M, Lee JH, Lee JH, Kim HJ, Yun SC, Lee KH (2014) Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study. Biol Blood Marrow Transplant 20:696\u2013704","journal-title":"Biol Blood Marrow Transplant"},{"key":"1143_CR33","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3389\/fimmu.2014.00122","volume":"5","author":"AS Chretien","year":"2014","unstructured":"Chretien AS, Le Roy A, Vey N, Prebet T, Blaise D, Fauriat C, Olive D (2014) Cancer-induced alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity. Front Immunol 5:122","journal-title":"Front Immunol"},{"key":"1143_CR34","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1158\/0008-5472.CAN-17-0799","volume":"77","author":"F Cichocki","year":"2017","unstructured":"Cichocki F, Valamehr B, Bjordahl R, Zhang B, Rezner B, Rogers P, Gaidarova S, Moreno S, Tuininga K, Dougherty P, Mccullar V, Howard P, Sarhan D, Taras E, Schlums H, Abbot S, Shoemaker D, Bryceson YT, Blazar BR, Wolchko S, Cooley S, Miller JS (2017) GSK3 inhibition drives maturation of NK cells and enhances their antitumor activity. Cancer Res 77:5664\u20135675","journal-title":"Cancer Res"},{"key":"1143_CR35","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1182\/blood-2017-08-752170","volume":"131","author":"S Cooley","year":"2018","unstructured":"Cooley S, Parham P, Miller JS (2018) Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. Blood 131:1053\u20131062","journal-title":"Blood"},{"key":"1143_CR36","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1158\/2326-6066.CIR-13-0171","volume":"2","author":"IP Silva Da","year":"2014","unstructured":"Da Silva IP, Gallois A, Jimenez-Baranda S, Khan S, Anderson AC, Kuchroo VK, Osman I, Bhardwaj N (2014) Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res 2:410\u2013422","journal-title":"Cancer Immunol Res"},{"key":"1143_CR37","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.4049\/jimmunol.1001220","volume":"185","author":"A Das","year":"2010","unstructured":"Das A, Long EO (2010) Lytic granule polarization, rather than degranulation, is the preferred target of inhibitory receptors in NK cells. J Immunol 185:4698\u20134704","journal-title":"J Immunol"},{"key":"1143_CR38","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ni.3470","volume":"17","author":"RB Delconte","year":"2016","unstructured":"Delconte RB, Kolesnik TB, Dagley LF, Rautela J, Shi W, Putz EM, Stannard K, Zhang JG, Teh C, Firth M, Ushiki T, Andoniou CE, Degli-Esposti MA, Sharp PP, Sanvitale CE, Infusini G, Liau NP, Linossi EM, Burns CJ, Carotta S, Gray DH, Seillet C, Hutchinson DS, Belz GT, Webb AI, Alexander WS, Li SS, Bullock AN, Babon JJ, Smyth MJ, Nicholson SE, Huntington ND (2016) CIS is a potent checkpoint in NK cell-mediated tumor immunity. Nat Immunol 17:816\u2013824","journal-title":"Nat Immunol"},{"key":"1143_CR39","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3389\/fimmu.2016.00351","volume":"7","author":"M Della Chiesa","year":"2016","unstructured":"Della Chiesa M, Pesce S, Muccio L, Carlomagno S, Sivori S, Moretta A, Marcenaro E (2016) Features of memory-like and PD-1(+) human NK cell subsets. Front Immunol 7:351","journal-title":"Front Immunol"},{"key":"1143_CR40","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3389\/fimmu.2015.00264","volume":"6","author":"A Domogala","year":"2015","unstructured":"Domogala A, Madrigal JA, Saudemont A (2015) Natural killer cell immunotherapy: from bench to bedside. Front Immunol 6:264","journal-title":"Front Immunol"},{"key":"1143_CR41","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/ni.1763","volume":"10","author":"Z Dong","year":"2009","unstructured":"Dong Z, Cruz-Munoz ME, Zhong MC, Chen R, Latour S, Veillette A (2009) Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells. Nat Immunol 10:973\u2013980","journal-title":"Nat Immunol"},{"key":"1143_CR42","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.immuni.2012.03.023","volume":"36","author":"Z Dong","year":"2012","unstructured":"Dong Z, Davidson D, Perez-Quintero LA, Kurosaki T, Swat W, Veillette A (2012) The adaptor SAP controls NK cell activation by regulating the enzymes Vav-1 and SHIP-1 and by enhancing conjugates with target cells. Immunity 36:974\u2013985","journal-title":"Immunity"},{"key":"1143_CR43","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/imr.12131","volume":"257","author":"G Dotti","year":"2014","unstructured":"Dotti G, Gottschalk S, Savoldo B, Brenner MK (2014) Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 257:107\u2013126","journal-title":"Immunol Rev"},{"key":"1143_CR44","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1074-7613(02)00429-6","volume":"17","author":"S Dubois","year":"2002","unstructured":"Dubois S, Mariner J, Waldmann TA, Tagaya Y (2002) IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 17:537\u2013547","journal-title":"Immunity"},{"key":"1143_CR45","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.4049\/jimmunol.180.4.2099","volume":"180","author":"S Dubois","year":"2008","unstructured":"Dubois S, Patel HJ, Zhang M, Waldmann TA, Muller JR (2008) Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+\/CD44 high T cells and its antitumor action. J Immunol 180:2099\u20132106","journal-title":"J Immunol"},{"key":"1143_CR46","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1158\/2326-6066.CIR-17-0279","volume":"5","author":"S Dubois","year":"2017","unstructured":"Dubois S, Conlon KC, Muller JR, Hsu-Albert J, Beltran N, Bryant BR, Waldmann TA (2017) IL15 infusion of cancer patients expands the subpopulation of cytotoxic CD56(bright) NK cells and increases NK-cell cytokine release capabilities. Cancer Immunol Res 5:929\u2013938","journal-title":"Cancer Immunol Res"},{"key":"1143_CR47","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/nri2144","volume":"7","author":"RA Eagle","year":"2007","unstructured":"Eagle RA, Trowsdale J (2007) Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 7:737\u2013744","journal-title":"Nat Rev Immunol"},{"key":"1143_CR48","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.smim.2017.07.009","volume":"31","author":"F Fang","year":"2017","unstructured":"Fang F, Xiao W, Tian Z (2017) NK cell-based immunotherapy for cancer. Semin Immunol 31:37\u201354","journal-title":"Semin Immunol"},{"key":"1143_CR49","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/blood-2005-08-027979","volume":"109","author":"C Fauriat","year":"2007","unstructured":"Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, Costello RT (2007) Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 109:323\u2013330","journal-title":"Blood"},{"key":"1143_CR50","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3389\/fonc.2018.00453","volume":"8","author":"AC Filley","year":"2018","unstructured":"Filley AC, Henriquez M, Dey M (2018) CART immunotherapy: development, success, and translation to malignant gliomas and other solid tumors. Front Oncol 8:453","journal-title":"Front Oncol"},{"key":"1143_CR51","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-015-0134-4","volume":"8","author":"V Folgiero","year":"2015","unstructured":"Folgiero V, Cifaldi L, Li Pira G, Goffredo BM, Vinti L, Locatelli F (2015) TIM-3\/Gal-9 interaction induces IFNgamma-dependent IDO1 expression in acute myeloid leukemia blast cells. J Hematol Oncol 8:36","journal-title":"J Hematol Oncol"},{"key":"1143_CR52","doi-asserted-by":"publisher","first-page":"e946365","DOI":"10.4161\/21624011.2014.946365","volume":"3","author":"A Gallois","year":"2014","unstructured":"Gallois A, Silva I, Osman I, Bhardwaj N (2014) Reversal of natural killer cell exhaustion by TIM-3 blockade. Oncoimmunology 3:e946365","journal-title":"Oncoimmunology"},{"key":"1143_CR53","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.ymthe.2018.02.025","volume":"26","author":"C Georgiadis","year":"2018","unstructured":"Georgiadis C, Preece R, Nickolay L, Etuk A, Petrova A, Ladon D, Danyi A, Humphryes-Kirilov N, Ajetunmobi A, Kim D, Kim JS, Qasim W (2018) Long terminal repeat CRISPR-CAR-coupled \u201cUniversal\u201d T cells mediate potent anti-leukemic effects. Mol Ther 26:1215\u20131227","journal-title":"Mol Ther"},{"key":"1143_CR54","doi-asserted-by":"publisher","first-page":"12878","DOI":"10.1038\/ncomms12878","volume":"7","author":"R Ghasemi","year":"2016","unstructured":"Ghasemi R, Lazear E, Wang X, Arefanian S, Zheleznyak A, Carreno BM, Higashikubo R, Gelman AE, Kreisel D, Fremont DH, Krupnick AS (2016) Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy. Nat Commun 7:12878","journal-title":"Nat Commun"},{"key":"1143_CR55","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1084\/jem.20081752","volume":"205","author":"S Gilfillan","year":"2008","unstructured":"Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS, Andrews DM, Smyth MJ, Colonna M (2008) DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 205:2965\u20132973","journal-title":"J Exp Med"},{"key":"1143_CR56","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fimmu.2013.00019","volume":"4","author":"M Gillard-Bocquet","year":"2013","unstructured":"Gillard-Bocquet M, Caer C, Cagnard N, Crozet L, Perez M, Fridman WH, Sautes-Fridman C, Cremer I (2013) Lung tumor microenvironment induces specific gene expression signature in intratumoral NK cells. Front Immunol 4:19","journal-title":"Front Immunol"},{"key":"1143_CR57","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.immuni.2008.02.016","volume":"28","author":"N Guerra","year":"2008","unstructured":"Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM, Raulet DH (2008) NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28:571\u2013580","journal-title":"Immunity"},{"key":"1143_CR58","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ni.3518","volume":"17","author":"C Guillerey","year":"2016","unstructured":"Guillerey C, Huntington ND, Smyth MJ (2016) Targeting natural killer cells in cancer immunotherapy. Nat Immunol 17:1025\u20131036","journal-title":"Nat Immunol"},{"key":"1143_CR59","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.4049\/jimmunol.1500300","volume":"195","author":"Y Guo","year":"2015","unstructured":"Guo Y, Luan L, Rabacal W, Bohannon JK, Fensterheim BA, Hernandez A, Sherwood ER (2015) IL-15 superagonist-mediated immunotoxicity: role of NK cells and IFN-gamma. J Immunol 195:2353\u20132364","journal-title":"J Immunol"},{"key":"1143_CR60","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","volume":"32","author":"J Gust","year":"2018","unstructured":"Gust J, Taraseviciute A, Turtle CJ (2018) Neurotoxicity associated with CD19-targeted CAR-T cell therapies. CNS Drugs 32:1091\u20131101","journal-title":"CNS Drugs"},{"key":"1143_CR61","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.4049\/jimmunol.0801878","volume":"182","author":"GG Halfteck","year":"2009","unstructured":"Halfteck GG, Elboim M, Gur C, Achdout H, Ghadially H, Mandelboim O (2009) Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46\/NCR1. J Immunol 182:2221\u20132230","journal-title":"J Immunol"},{"key":"1143_CR62","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15252\/emmm.201607485","volume":"9","author":"J Hartmann","year":"2017","unstructured":"Hartmann J, Schussler-Lenz M, Bondanza A, Buchholz CJ (2017) Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med 9:1183\u20131197","journal-title":"EMBO Mol Med"},{"key":"1143_CR63","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.4049\/jimmunol.1000951","volume":"186","author":"TD Holmes","year":"2011","unstructured":"Holmes TD, El-Sherbiny YM, Davison A, Clough SL, Blair GE, Cook GP (2011) A human NK cell activation\/inhibition threshold allows small changes in the target cell surface phenotype to dramatically alter susceptibility to NK cells. J Immunol 186:1538\u20131545","journal-title":"J Immunol"},{"key":"1143_CR64","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","volume":"128","author":"J Hsu","year":"2018","unstructured":"Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, Azimi CS, Scheer AK, Randolph HE, Thompson TW, Zhang L, Iannello A, Mathur N, Jardine KE, Kirn GA, Bell JC, Mcburney MW, Raulet DH, Ardolino M (2018) Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade. J Clin Invest 128:4654\u20134668","journal-title":"J Clin Invest"},{"key":"1143_CR65","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1600-065X.2008.00655.x","volume":"224","author":"F Huang","year":"2008","unstructured":"Huang F, Gu H (2008) Negative regulation of lymphocyte development and function by the Cbl family of proteins. Immunol Rev 224:229\u2013238","journal-title":"Immunol Rev"},{"key":"1143_CR66","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.3892\/ol.2017.5891","volume":"13","author":"R Huang","year":"2017","unstructured":"Huang R, Zhang D, Li F, Xiao Z, Wu M, Shi D, Xiang P, Bao Z (2017) Loss of Fas expression and high expression of HLA-E promoting the immune escape of early colorectal cancer cells. Oncol Lett 13:3379\u20133386","journal-title":"Oncol Lett"},{"key":"1143_CR67","doi-asserted-by":"publisher","first-page":"e1466769","DOI":"10.1080\/2162402X.2018.1466769","volume":"7","author":"AL Hung","year":"2018","unstructured":"Hung AL, Maxwell R, Theodros D, Belcaid Z, Mathios D, Luksik AS, Kim E, Wu A, Xia Y, Garzon-Muvdi T, Jackson C, Ye X, Tyler B, Selby M, Korman A, Barnhart B, Park SM, Youn JI, Chowdhury T, Park CK, Brem H, Pardoll DM, Lim M (2018) TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncoimmunology 7:e1466769","journal-title":"Oncoimmunology"},{"key":"1143_CR68","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood-2014-02-556837","volume":"124","author":"M Imamura","year":"2014","unstructured":"Imamura M, Shook D, Kamiya T, Shimasaki N, Chai SM, Coustan-Smith E, Imai C, Campana D (2014) Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. Blood 124:1081\u20131088","journal-title":"Blood"},{"key":"1143_CR69","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/mt.2014.50","volume":"22","author":"S Ito","year":"2014","unstructured":"Ito S, Bollard CM, Carlsten M, Melenhorst JJ, Biancotto A, Wang E, Chen J, Kotliarov Y, Cheung F, Xie Z, Marincola F, Tanimoto K, Battiwalla M, Olnes MJ, Perl S, Schum P, Hughes TE, Keyvanfar K, Hensel N, Muranski P, Young NS, Barrett AJ (2014) Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. Mol Ther 22:1388\u20131395","journal-title":"Mol Ther"},{"key":"1143_CR70","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1158\/0008-5472.CAN-14-2788","volume":"75","author":"HB Jie","year":"2015","unstructured":"Jie HB, Schuler PJ, Lee SC, Srivastava RM, Argiris A, Ferrone S, Whiteside TL, Ferris RL (2015) CTLA-4(+) regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res 75:2200\u20132210","journal-title":"Cancer Res"},{"key":"1143_CR71","doi-asserted-by":"publisher","first-page":"ra102","DOI":"10.1126\/scisignal.2004373","volume":"6","author":"RP Joshi","year":"2013","unstructured":"Joshi RP, Schmidt AM, Das J, Pytel D, Riese MJ, Lester M, Diehl JA, Behrens EM, Kambayashi T, Koretzky GA (2013) The zeta isoform of diacylglycerol kinase plays a predominant role in regulatory T cell development and TCR-mediated ras signaling. Sci Signal 6:ra102","journal-title":"Sci Signal"},{"key":"1143_CR72","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/319675a0","volume":"319","author":"K Karre","year":"1986","unstructured":"Karre K, Ljunggren HG, Piontek G, Kiessling R (1986) Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319:675\u2013678","journal-title":"Nature"},{"key":"1143_CR73","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fonc.2012.00191","volume":"2","author":"P Kaur","year":"2012","unstructured":"Kaur P, Asea A (2012) Radiation-induced effects and the immune system in cancer. Front Oncol 2:191","journal-title":"Front Oncol"},{"key":"1143_CR74","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12:6106\u20136115","journal-title":"Clin Cancer Res"},{"key":"1143_CR75","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/eji.1830050208","volume":"5","author":"R Kiessling","year":"1975","unstructured":"Kiessling R, Klein E, Wigzell H (1975) \u201cNatural\u201d killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 5:112\u2013117","journal-title":"Eur J Immunol"},{"key":"1143_CR76","doi-asserted-by":"publisher","first-page":"189","DOI":"10.5045\/br.2015.50.4.189","volume":"50","author":"HS Kim","year":"2015","unstructured":"Kim HS (2015) A multifaceted approach targeting NK cells for better treatment of cancer: focus on hematological malignancies. Blood Res 50:189\u2013191","journal-title":"Blood Res"},{"key":"1143_CR77","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.3389\/fimmu.2018.02041","volume":"9","author":"N Kim","year":"2018","unstructured":"Kim N, Kim HS (2018) Targeting checkpoint receptors and molecules for therapeutic modulation of natural killer cells. Front Immunol 9:2041","journal-title":"Front Immunol"},{"key":"1143_CR78","first-page":"49","volume":"5","author":"HS Kim","year":"2012","unstructured":"Kim HS, Long EO (2012) Complementary phosphorylation sites in the adaptor protein SLP-76 promote synergistic activation of natural killer cells. Sci Signal 5:49","journal-title":"Sci Signal"},{"key":"1143_CR79","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nature03847","volume":"436","author":"S Kim","year":"2005","unstructured":"Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, French AR, Sunwoo JB, Lemieux S, Hansen TH, Yokoyama WM (2005) Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436:709\u2013713","journal-title":"Nature"},{"key":"1143_CR80","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.immuni.2010.02.004","volume":"32","author":"HS Kim","year":"2010","unstructured":"Kim HS, Das A, Gross CC, Bryceson YT, Long EO (2010) Synergistic signals for natural cytotoxicity are required to overcome inhibition by c-Cbl ubiquitin ligase. Immunity 32:175\u2013186","journal-title":"Immunity"},{"key":"1143_CR81","doi-asserted-by":"crossref","first-page":"16130","DOI":"10.18632\/oncotarget.7470","volume":"7","author":"PS Kim","year":"2016","unstructured":"Kim PS, Kwilas AR, Xu W, Alter S, Jeng EK, Wong HC, Schlom J, Hodge JW (2016) IL-15 superagonist\/IL-15RalphaSushi-Fc fusion complex (IL-15SA\/IL-15RalphaSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8\u2009+\u2009T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. Oncotarget 7:16130\u201316145","journal-title":"Oncotarget"},{"key":"1143_CR82","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1089\/hum.2017.157","volume":"28","author":"S Kloss","year":"2017","unstructured":"Kloss S, Oberschmidt O, Morgan M, Dahlke J, Arseniev L, Huppert V, Granzin M, Gardlowski T, Matthies N, Soltenborn S, Schambach A, Koehl U (2017) Optimization of human NK cell manufacturing: fully automated separation, improved ex vivo expansion using IL-21 with autologous feeder cells, and generation of anti-CD123-CAR-expressing effector cells. Hum Gene Ther 28:897\u2013913","journal-title":"Hum Gene Ther"},{"key":"1143_CR83","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1182\/blood-2013-08-519199","volume":"123","author":"HE Kohrt","year":"2014","unstructured":"Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F, Fuseri N, Bonnafous C, Czerwinski D, Rajapaksa A, Waller E, Ugolini S, Vivier E, Romagne F, Levy R, Blery M, Andre P (2014) Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123:678\u2013686","journal-title":"Blood"},{"key":"1143_CR84","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.4049\/jimmunol.173.6.3594","volume":"173","author":"R Koka","year":"2004","unstructured":"Koka R, Burkett P, Chien M, Chai S, Boone DL, Ma A (2004) Cutting edge: murine dendritic cells require IL-15R alpha to prime NK cells. J Immunol 173:3594\u20133598","journal-title":"J Immunol"},{"key":"1143_CR85","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.3892\/or.2015.4149","volume":"34","author":"H Komita","year":"2015","unstructured":"Komita H, Koido S, Hayashi K, Kan S, Ito M, Kamata Y, Suzuki M, Homma S (2015) Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3\/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors. Oncol Rep 34:2099\u20132105","journal-title":"Oncol Rep"},{"key":"1143_CR86","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41423-018-0168-y","volume":"16","author":"P Kucan Brlic","year":"2018","unstructured":"Kucan Brlic P, Lenac Rovis T, Cinamon G, Tsukerman P, Mandelboim O, Jonjic S (2018) Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cell Mol Immunol 16:40\u201352","journal-title":"Cell Mol Immunol"},{"key":"1143_CR87","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cellsig.2015.05.012","volume":"27","author":"HJ Kwon","year":"2015","unstructured":"Kwon HJ, Kwon SJ, Lee H, Park HR, Choi GE, Kang SW, Kwon SW, Kim N, Lee SY, Ryu S, Kim SC, Kim HS (2015) NK cell function triggered by multiple activating receptors is negatively regulated by glycogen synthase kinase-3beta. Cell Signal 27:1731\u20131741","journal-title":"Cell Signal"},{"key":"1143_CR88","doi-asserted-by":"publisher","first-page":"11686","DOI":"10.1038\/ncomms11686","volume":"7","author":"HJ Kwon","year":"2016","unstructured":"Kwon HJ, Choi GE, Ryu S, Kwon SJ, Kim SC, Booth C, Nichols KE, Kim HS (2016) Stepwise phosphorylation of p65 promotes NF-kappaB activation and NK cell responses during target cell recognition. Nat Commun 7:11686","journal-title":"Nat Commun"},{"key":"1143_CR89","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1038\/emm.2017.42","volume":"49","author":"HJ Kwon","year":"2017","unstructured":"Kwon HJ, Kim N, Kim HS (2017) Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy. Exp Mol Med 49:e311","journal-title":"Exp Mol Med"},{"key":"1143_CR90","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/(SICI)1521-4141(199803)28:03<780::AID-IMMU780>3.0.CO;2-8","volume":"28","author":"S Lang","year":"1998","unstructured":"Lang S, Vujanovic NL, Wollenberg B, Whiteside TL (1998) Absence of B7.1-CD28\/CTLA-4-mediated co-stimulation in human NK cells. Eur J Immunol 28:780\u2013786","journal-title":"Eur J Immunol"},{"key":"1143_CR91","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","volume":"23","author":"LL Lanier","year":"2005","unstructured":"Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23:225\u2013274","journal-title":"Annu Rev Immunol"},{"key":"1143_CR92","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ni1581","volume":"9","author":"LL Lanier","year":"2008","unstructured":"Lanier LL (2008) Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9:495\u2013502","journal-title":"Nat Immunol"},{"key":"1143_CR93","doi-asserted-by":"publisher","first-page":"e1395123","DOI":"10.1080\/2162402X.2017.1395123","volume":"7","author":"PM Lanuza","year":"2018","unstructured":"Lanuza PM, Vigueras A, Olivan S, Prats AC, Costas S, Llamazares G, Sanchez-Martinez D, Ayuso JM, Fernandez L, Ochoa I, Pardo J (2018) Activated human primary NK cells efficiently kill colorectal cancer cells in 3D spheroid cultures irrespectively of the level of PD-L1 expression. Oncoimmunology 7:e1395123","journal-title":"Oncoimmunology"},{"key":"1143_CR94","doi-asserted-by":"publisher","first-page":"e87131","DOI":"10.1371\/journal.pone.0087131","volume":"9","author":"D Lehmann","year":"2014","unstructured":"Lehmann D, Spanholtz J, Sturtzel C, Tordoir M, Schlechta B, Groenewegen D, Hofer E (2014) IL-12 directs further maturation of ex vivo differentiated NK cells with improved therapeutic potential. PLoS ONE 9:e87131","journal-title":"PLoS ONE"},{"key":"1143_CR95","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.bbmt.2014.01.006","volume":"20","author":"JW Leong","year":"2014","unstructured":"Leong JW, Chase JM, Romee R, Schneider SE, Sullivan RP, Cooper MA, Fehniger TA (2014) Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol Blood Marrow Transplant 20:463\u2013473","journal-title":"Biol Blood Marrow Transplant"},{"issue":"181\u2013192","key":"1143_CR96","first-page":"e5","volume":"23","author":"Y Li","year":"2018","unstructured":"Li Y, Hermanson DL, Moriarity BS, Kaufman DS (2018) Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell 23(181\u2013192):e5","journal-title":"Cell Stem Cell"},{"key":"1143_CR97","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20061856","volume":"204","author":"CH Liu","year":"2007","unstructured":"Liu CH, Machado FS, Guo R, Nichols KE, Burks AW, Aliberti JC, Zhong XP (2007) Diacylglycerol kinase zeta regulates microbial recognition and host resistance to Toxoplasma gondii. J Exp Med 204:781\u2013792","journal-title":"J Exp Med"},{"key":"1143_CR98","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.immuni.2012.03.007","volume":"36","author":"D Liu","year":"2012","unstructured":"Liu D, Peterson ME, Long EO (2012) The adaptor protein Crk controls activation and inhibition of natural killer cells. Immunity 36:600\u2013611","journal-title":"Immunity"},{"key":"1143_CR99","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/cr.2016.142","volume":"27","author":"X Liu","year":"2017","unstructured":"Liu X, Zhang Y, Cheng C, Cheng AW, Zhang X, Li N, Xia C, Wei X, Liu X, Wang H (2017) CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res 27:154\u2013157","journal-title":"Cell Res"},{"key":"1143_CR100","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, Gagea M, Banerjee P, Cai R, Bdaiwi MH, Basar R, Muftuoglu M, Li L, Marin D, Wierda W, Keating M, Champlin R, Shpall E, Rezvani K (2018) Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32:520\u2013531","journal-title":"Leukemia"},{"key":"1143_CR101","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1600-065X.2008.00660.x","volume":"224","author":"EO Long","year":"2008","unstructured":"Long EO (2008) Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev 224:70\u201384","journal-title":"Immunol Rev"},{"key":"1143_CR102","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","volume":"31","author":"EO Long","year":"2013","unstructured":"Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S (2013) Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 31:227\u2013258","journal-title":"Annu Rev Immunol"},{"key":"1143_CR103","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ccell.2017.06.009","volume":"32","author":"A Lopez-Soto","year":"2017","unstructured":"Lopez-Soto A, Gonzalez S, Smyth MJ, Galluzzi L (2017) Control of metastasis by NK cells. Cancer Cell 32:135\u2013154","journal-title":"Cancer Cell"},{"key":"1143_CR104","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.molimm.2017.06.025","volume":"88","author":"E Lusty","year":"2017","unstructured":"Lusty E, Poznanski SM, Kwofie K, Mandur TS, Lee DA, Richards CD, Ashkar AA (2017) IL-18\/IL-15\/IL-12 synergy induces elevated and prolonged IFN-gamma production by ex vivo expanded NK cells which is not due to enhanced STAT4 activation. Mol Immunol 88:138\u2013147","journal-title":"Mol Immunol"},{"key":"1143_CR105","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ccr.2012.03.003","volume":"21","author":"JA Magee","year":"2012","unstructured":"Magee JA, Piskounova E, Morrison SJ (2012) Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21:283\u2013296","journal-title":"Cancer Cell"},{"key":"1143_CR106","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.smim.2017.08.002","volume":"31","author":"KJ Malmberg","year":"2017","unstructured":"Malmberg KJ, Carlsten M, Bjorklund A, Sohlberg E, Bryceson YT, Ljunggren HG (2017) Natural killer cell-mediated immunosurveillance of human cancer. Semin Immunol 31:20\u201329","journal-title":"Semin Immunol"},{"key":"1143_CR107","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3389\/fimmu.2013.00450","volume":"4","author":"A Marcais","year":"2013","unstructured":"Marcais A, Viel S, Grau M, Henry T, Marvel J, Walzer T (2013) Regulation of mouse NK cell development and function by cytokines. Front Immunol 4:450","journal-title":"Front Immunol"},{"key":"1143_CR108","doi-asserted-by":"publisher","first-page":"e1226720","DOI":"10.1080\/2162402X.2016.1226720","volume":"5","author":"EM Mcwilliams","year":"2016","unstructured":"Mcwilliams EM, Mele JM, Cheney C, Timmerman EA, Fiazuddin F, Strattan EJ, Mo X, Byrd JC, Muthusamy N, Awan FT (2016) Therapeutic CD94\/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. Oncoimmunology 5:e1226720","journal-title":"Oncoimmunology"},{"key":"1143_CR109","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3389\/fimmu.2013.00481","volume":"4","author":"A Mentlik James","year":"2013","unstructured":"Mentlik James A, Cohen AD, Campbell KS (2013) Combination immune therapies to enhance anti-tumor responses by NK cells. Front Immunol 4:481","journal-title":"Front Immunol"},{"key":"1143_CR110","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3389\/fimmu.2017.01850","volume":"8","author":"HR Mirzaei","year":"2017","unstructured":"Mirzaei HR, Rodriguez A, Shepphird J, Brown CE, Badie B (2017) Chimeric antigen receptors T cell therapy in solid tumor: challenges and clinical applications. Front Immunol 8:1850","journal-title":"Front Immunol"},{"key":"1143_CR111","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/nri956","volume":"2","author":"A Moretta","year":"2002","unstructured":"Moretta A (2002) Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2:957\u2013964","journal-title":"Nat Rev Immunol"},{"key":"1143_CR112","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/sj.emboj.7600019","volume":"23","author":"L Moretta","year":"2004","unstructured":"Moretta L, Moretta A (2004) Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 23:255\u2013259","journal-title":"EMBO J"},{"key":"1143_CR113","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc.2015.5","volume":"16","author":"MG Morvan","year":"2016","unstructured":"Morvan MG, Lanier LL (2016) NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer 16:7\u201319","journal-title":"Nat Rev Cancer"},{"key":"1143_CR114","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O\u2019rourke","year":"2017","unstructured":"O\u2019rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV (2017) A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 9:eaaa0984","journal-title":"Sci Transl Med"},{"key":"1143_CR115","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.4049\/jimmunol.156.12.4531","volume":"156","author":"L Olcese","year":"1996","unstructured":"Olcese L, Lang P, Vely F, Cambiaggi A, Marguet D, Blery M, Hippen KL, Biassoni R, Moretta A, Moretta L, Cambier JC, Vivier E (1996) Human and mouse killer-cell inhibitory receptors recruit PTP1C and PTP1D protein tyrosine phosphatases. J Immunol 156:4531\u20134534","journal-title":"J Immunol"},{"key":"1143_CR116","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1093\/infdis\/jiy034","volume":"217","author":"P Paidipally","year":"2018","unstructured":"Paidipally P, Tripathi D, Van A, Radhakrishnan RK, Dhiman R, Venkatasubramanian S, Devalraju KP, Tvinnereim AR, Valluri VL, Vankayalapati R (2018) Interleukin-21 regulates natural killer cell responses during mycobacterium tuberculosis infection. J Infect Dis 217:1323\u20131333","journal-title":"J Infect Dis"},{"key":"1143_CR117","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nature12998","volume":"507","author":"M Paolino","year":"2014","unstructured":"Paolino M, Choidas A, Wallner S, Pranjic B, Uribesalgo I, Loeser S, Jamieson AM, Langdon WY, Ikeda F, Fededa JP, Cronin SJ, Nitsch R, Schultz-Fademrecht C, Eickhoff J, Menninger S, Unger A, Torka R, Gruber T, Hinterleitner R, Baier G, Wolf D, Ullrich A, Klebl BM, Penninger JM (2014) The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature 507:508\u2013512","journal-title":"Nature"},{"key":"1143_CR118","doi-asserted-by":"publisher","first-page":"11154","DOI":"10.1038\/ncomms11154","volume":"7","author":"R Parameswaran","year":"2016","unstructured":"Parameswaran R, Ramakrishnan P, Moreton SA, Xia Z, Hou Y, Lee DA, Gupta K, Delima M, Beck RC, Wald DN (2016) Repression of GSK3 restores NK cell cytotoxicity in AML patients. Nat Commun 7:11154","journal-title":"Nat Commun"},{"key":"1143_CR119","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/sj.mt.6300104","volume":"15","author":"JR Park","year":"2007","unstructured":"Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, Meechoovet HB, Bautista C, Chang WC, Ostberg JR, Jensen MC (2007) Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 15:825\u2013833","journal-title":"Mol Ther"},{"key":"1143_CR120","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1084\/jem.192.3.337","volume":"192","author":"S Parolini","year":"2000","unstructured":"Parolini S, Bottino C, Falco M, Augugliaro R, Giliani S, Franceschini R, Ochs HD, Wolf H, Bonnefoy JY, Biassoni R, Moretta L, Notarangelo LD, Moretta A (2000) X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med 192:337\u2013346","journal-title":"J Exp Med"},{"key":"1143_CR121","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.jcyt.2015.07.011","volume":"17","author":"A Perez-Martinez","year":"2015","unstructured":"Perez-Martinez A, Fernandez L, Valentin J, Martinez-Romera I, Corral MD, Ramirez M, Abad L, Santamaria S, Gonzalez-Vicent M, Sirvent S, Sevilla J, Vicario JL, De Prada I, Diaz MA (2015) A phase I\/II trial of interleukin-15-stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors. Cytotherapy 17:1594\u20131603","journal-title":"Cytotherapy"},{"key":"1143_CR122","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jaci.2016.04.025","volume":"139","author":"S Pesce","year":"2016","unstructured":"Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, Moretta L, Moretta A, Marcenaro E (2016) Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. J Allergy Clin Immunol 139:335\u2013346","journal-title":"J Allergy Clin Immunol"},{"key":"1143_CR123","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/intimm\/dxp047","volume":"21","author":"G Pietra","year":"2009","unstructured":"Pietra G, Manzini C, Vitale M, Balsamo M, Ognio E, Boitano M, Queirolo P, Moretta L, Mingari MC (2009) Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol 21:793\u2013801","journal-title":"Int Immunol"},{"key":"1143_CR124","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3389\/fimmu.2015.00230","volume":"6","author":"G Pittari","year":"2015","unstructured":"Pittari G, Filippini P, Gentilcore G, Grivel JC, Rutella S (2015) Revving up natural killer cells and cytokine-induced killer cells against hematological malignancies. Front Immunol 6:230","journal-title":"Front Immunol"},{"key":"1143_CR125","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1158\/0008-5472.CAN-10-4179","volume":"71","author":"S Platonova","year":"2011","unstructured":"Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P, Andre P, Dieu-Nosjean MC, Alifano M, Regnard JF, Fridman WH, Sautes-Fridman C, Cremer I (2011) Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 71:5412\u20135422","journal-title":"Cancer Res"},{"key":"1143_CR126","first-page":"226","volume":"21","author":"HF Pross","year":"1975","unstructured":"Pross HF, Jondal M (1975) Cytotoxic lymphocytes from normal donors. A functional marker of human non-T lymphocytes. Clin Exp Immunol 21:226\u2013235","journal-title":"Clin Exp Immunol"},{"key":"1143_CR127","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nri2604","volume":"9","author":"DH Raulet","year":"2009","unstructured":"Raulet DH, Guerra N (2009) Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol 9:568\u2013580","journal-title":"Nat Rev Immunol"},{"key":"1143_CR128","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-immunol-032712-095951","volume":"31","author":"DH Raulet","year":"2013","unstructured":"Raulet DH, Gasser S, Gowen BG, Deng W, Jung H (2013) Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 31:413\u2013441","journal-title":"Annu Rev Immunol"},{"key":"1143_CR129","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","volume":"23","author":"J Ren","year":"2017","unstructured":"Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y (2017) Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res 23:2255\u20132266","journal-title":"Clin Cancer Res"},{"key":"1143_CR130","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3389\/fimmu.2015.00578","volume":"6","author":"K Rezvani","year":"2015","unstructured":"Rezvani K, Rouce RH (2015) The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol 6:578","journal-title":"Front Immunol"},{"key":"1143_CR131","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","volume":"25","author":"K Rezvani","year":"2017","unstructured":"Rezvani K, Rouce R, Liu E, Shpall E (2017) Engineering Natural killer cells for cancer immunotherapy. Mol Ther 25:1769\u20131781","journal-title":"Mol Ther"},{"key":"1143_CR132","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3410\/M3-9","volume":"3","author":"F Romagne","year":"2011","unstructured":"Romagne F, Vivier E (2011) Natural killer cell-based therapies. F1000 Med Rep 3:9","journal-title":"F1000 Med Rep"},{"key":"1143_CR133","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","volume":"313","author":"SA Rosenberg","year":"1985","unstructured":"Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485\u20131492","journal-title":"N Engl J Med"},{"key":"1143_CR134","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097\u20132100","journal-title":"Science"},{"key":"1143_CR135","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3324\/haematol.2015.135301","volume":"101","author":"L Ruggeri","year":"2016","unstructured":"Ruggeri L, Urbani E, Andre P, Mancusi A, Tosti A, Topini F, Blery M, Animobono L, Romagne F, Wagtmann N, Velardi A (2016) Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells. Haematologica 101:626\u2013633","journal-title":"Haematologica"},{"key":"1143_CR136","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/imr.12319","volume":"267","author":"PM Saunders","year":"2015","unstructured":"Saunders PM, Vivian JP, O\u2019connor GM, Sullivan LC, Pymm P, Rossjohn J, Brooks AG (2015) A bird\u2019s eye view of NK cell receptor interactions with their MHC class I ligands. Immunol Rev 267:148\u2013166","journal-title":"Immunol Rev"},{"key":"1143_CR137","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1126\/scisignal.2004411","volume":"6","author":"AM Schmidt","year":"2013","unstructured":"Schmidt AM, Zou T, Joshi RP, Leichner TM, Pimentel MA, Sommers CL, Kambayashi T (2013) Diacylglycerol kinase zeta limits the generation of natural regulatory T cells. Sci Signal 6:101","journal-title":"Sci Signal"},{"key":"1143_CR138","doi-asserted-by":"publisher","first-page":"15776","DOI":"10.1038\/ncomms15776","volume":"8","author":"H Seo","year":"2017","unstructured":"Seo H, Jeon I, Kim BS, Park M, Bae EA, Song B, Koh CH, Shin KS, Kim IK, Choi K, Oh T, Min J, Min BS, Han YD, Kang SJ, Shin SJ, Chung Y, Kang CY (2017) IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours. Nat Commun 8:15776","journal-title":"Nat Commun"},{"key":"1143_CR139","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1182\/blood-2014-07-592881","volume":"125","author":"NN Shah","year":"2015","unstructured":"Shah NN, Baird K, Delbrook CP, Fleisher TA, Kohler ME, Rampertaap S, Lemberg K, Hurley CK, Kleiner DE, Merchant MS, Pittaluga S, Sabatino M, Stroncek DF, Wayne AS, Zhang H, Fry TJ, Mackall CL (2015) Acute GVHD in patients receiving IL-15\/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. Blood 125:784\u2013792","journal-title":"Blood"},{"key":"1143_CR140","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1158\/2326-6066.CIR-15-0195","volume":"4","author":"GC Sim","year":"2016","unstructured":"Sim GC, Liu C, Wang E, Liu H, Creasy C, Dai Z, Overwijk WW, Roszik J, Marincola F, Hwu P, Grimm E, Radvanyi L (2016) IL2 variant circumvents ICOS\u2009+\u2009regulatory T-cell expansion and promotes NK cell activation. Cancer Immunol Res 4:983\u2013994","journal-title":"Cancer Immunol Res"},{"key":"1143_CR141","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1365-2567.2007.02730.x","volume":"123","author":"K Skak","year":"2008","unstructured":"Skak K, Frederiksen KS, Lundsgaard D (2008) Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology 123:575\u2013583","journal-title":"Immunology"},{"key":"1143_CR142","doi-asserted-by":"publisher","first-page":"6291","DOI":"10.1128\/MCB.23.17.6291-6299.2003","volume":"23","author":"CC Stebbins","year":"2003","unstructured":"Stebbins CC, Watzl C, Billadeau DD, Leibson PJ, Burshtyn DN, Long EO (2003) Vav1 dephosphorylation by the tyrosine phosphatase SHP-1 as a mechanism for inhibition of cellular cytotoxicity. Mol Cell Biol 23:6291\u20136299","journal-title":"Mol Cell Biol"},{"key":"1143_CR143","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.4049\/jimmunol.1302091","volume":"192","author":"A Stojanovic","year":"2014","unstructured":"Stojanovic A, Fiegler N, Brunner-Weinzierl M, Cerwenka A (2014) CTLA-4 is expressed by activated mouse NK cells and inhibits NK Cell IFN-gamma production in response to mature dendritic cells. J Immunol 192:4184\u20134191","journal-title":"J Immunol"},{"key":"1143_CR144","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","volume":"65","author":"G Suck","year":"2016","unstructured":"Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG, Tonn T (2016) NK-92: an \u2018off-the-shelf therapeutic\u2019 for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol Immunother 65:485\u2013492","journal-title":"Cancer Immunol Immunother"},{"key":"1143_CR145","doi-asserted-by":"publisher","first-page":"e1264562","DOI":"10.1080\/2162402X.2016.1264562","volume":"6","author":"C Sun","year":"2017","unstructured":"Sun C, Xu J, Huang Q, Huang M, Wen H, Zhang C, Wang J, Song J, Zheng M, Sun H, Wei H, Xiao W, Sun R, Tian Z (2017) High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer. Oncoimmunology 6:e1264562","journal-title":"Oncoimmunology"},{"key":"1143_CR146","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/CJI.0000000000000059","volume":"38","author":"S Szmania","year":"2015","unstructured":"Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, Van Rhee F (2015) Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother 38:24\u201336","journal-title":"J Immunother"},{"key":"1143_CR147","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000357802","volume":"7","author":"G Tabellini","year":"2014","unstructured":"Tabellini G, Benassi M, Marcenaro E, Coltrini D, Patrizi O, Ricotta D, Rampinelli F, Moretta A, Parolini S (2014) Primitive neuroectodermal tumor in an ovarian cystic teratoma: natural killer and neuroblastoma cell analysis. Case Rep Oncol 7:70\u201378","journal-title":"Case Rep Oncol"},{"key":"1143_CR148","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1074-7613(00)80543-9","volume":"8","author":"K Takeda","year":"1998","unstructured":"Takeda K, Tsutsui H, Yoshimoto T, Adachi O, Yoshida N, Kishimoto T, Okamura H, Nakanishi K, Akira S (1998) Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 8:383\u2013390","journal-title":"Immunity"},{"key":"1143_CR149","doi-asserted-by":"publisher","first-page":"e1261242","DOI":"10.1080\/2162402X.2016.1261242","volume":"6","author":"R Tallerico","year":"2017","unstructured":"Tallerico R, Cristiani CM, Staaf E, Garofalo C, Sottile R, Capone M, Pico De Coana Y, Madonna G, Palella E, Wolodarski M, Carannante V, Mallardo D, Simeone E, Grimaldi AM, Johansson S, Frumento P, Gulletta E, Anichini A, Colucci F, Ciliberto G, Kiessling R, Karre K, Ascierto PA, Carbone E (2017) IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. Oncoimmunology 6:e1261242","journal-title":"Oncoimmunology"},{"key":"1143_CR150","first-page":"1083","volume":"8","author":"X Tang","year":"2018","unstructured":"Tang X, Yang L, Li Z, Nalin AP, Dai H, Xu T, Yin J, You F, Zhu M, Shen W, Chen G, Zhu X, Wu D, Yu J (2018) First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res 8:1083\u20131089","journal-title":"Am J Cancer Res"},{"key":"1143_CR151","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.coi.2012.01.001","volume":"24","author":"A Thielens","year":"2012","unstructured":"Thielens A, Vivier E, Romagne F (2012) NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr Opin Immunol 24:239\u2013245","journal-title":"Curr Opin Immunol"},{"key":"1143_CR152","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.4049\/jimmunol.1400330","volume":"194","author":"K Topfer","year":"2015","unstructured":"Topfer K, Cartellieri M, Michen S, Wiedemuth R, Muller N, Lindemann D, Bachmann M, Fussel M, Schackert G, Temme A (2015) DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J Immunol 194:3201\u20133212","journal-title":"J Immunol"},{"key":"1143_CR153","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/ni1325","volume":"7","author":"JL Upshaw","year":"2006","unstructured":"Upshaw JL, Arneson LN, Schoon RA, Dick CJ, Billadeau DD, Leibson PJ (2006) NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat Immunol 7:524\u2013532","journal-title":"Nat Immunol"},{"key":"1143_CR154","doi-asserted-by":"crossref","first-page":"56968","DOI":"10.18632\/oncotarget.18185","volume":"8","author":"JRM Audenaerde Van","year":"2017","unstructured":"Van Audenaerde JRM, De Waele J, Marcq E, Van Loenhout J, Lion E, Van Den Bergh JMJ, Jesenofsky R, Masamune A, Roeyen G, Pauwels P, Lardon F, Peeters M, Smits ELJ (2017) Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. Oncotarget 8:56968\u201356979","journal-title":"Oncotarget"},{"key":"1143_CR155","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3389\/fimmu.2017.00631","volume":"8","author":"JP Veluchamy","year":"2017","unstructured":"Veluchamy JP, Kok N, Van Der Vliet HJ, Verheul HMW, De Gruijl TD, Spanholtz J (2017) The rise of allogeneic natural killer cells as a platform for cancer immunotherapy: recent innovations and future developments. Front Immunol 8:631","journal-title":"Front Immunol"},{"key":"1143_CR156","doi-asserted-by":"publisher","first-page":"17675","DOI":"10.18632\/oncotarget.24832","volume":"9","author":"N Vey","year":"2018","unstructured":"Vey N, Karlin L, Sadot-Lebouvier S, Broussais F, Berton-Rigaud D, Rey J, Charbonnier A, Marie D, Andre P, Paturel C, Zerbib R, Bennouna J, Salles G, Goncalves A (2018) A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. Oncotarget 9:17675\u201317688","journal-title":"Oncotarget"},{"key":"1143_CR157","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","volume":"9","author":"E Vivier","year":"2008","unstructured":"Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9:503\u2013510","journal-title":"Nat Immunol"},{"key":"1143_CR158","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","volume":"331","author":"E Vivier","year":"2011","unstructured":"Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331:44\u201349","journal-title":"Science"},{"key":"1143_CR159","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nri3174","volume":"12","author":"E Vivier","year":"2012","unstructured":"Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L (2012) Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 12:239\u2013252","journal-title":"Nat Rev Immunol"},{"key":"1143_CR160","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3109\/08820139.2015.1052145","volume":"44","author":"Z Wang","year":"2015","unstructured":"Wang Z, Zhu J, Gu H, Yuan Y, Zhang B, Zhu D, Zhou J, Zhu Y, Chen W (2015) The clinical significance of abnormal Tim-3 expression on NK cells from patients with gastric cancer. Immunol Invest 44:578\u2013589","journal-title":"Immunol Invest"},{"key":"1143_CR161","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJM198704093161502","volume":"316","author":"WH West","year":"1987","unstructured":"West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898\u2013905","journal-title":"N Engl J Med"},{"key":"1143_CR162","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/jmcb\/mjq012","volume":"2","author":"Z Wu","year":"2010","unstructured":"Wu Z, Xu Y (2010) IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8\u2009+\u2009T cells proliferation and activation. J Mol Cell Biol 2:217\u2013222","journal-title":"J Mol Cell Biol"},{"key":"1143_CR163","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ymthe.2018.01.020","volume":"26","author":"W Xiong","year":"2018","unstructured":"Xiong W, Chen Y, Kang X, Chen Z, Zheng P, Hsu YH, Jang JH, Qin L, Liu H, Dotti G, Liu D (2018) Immunological synapse predicts effectiveness of chimeric antigen receptor cells. Mol Ther 26:963\u2013975","journal-title":"Mol Ther"},{"key":"1143_CR164","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.intimp.2015.09.017","volume":"29","author":"L Xu","year":"2015","unstructured":"Xu L, Huang Y, Tan L, Yu W, Chen D, Lu C, He J, Wu G, Liu X, Zhang Y (2015) Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol 29:635\u2013641","journal-title":"Int Immunopharmacol"},{"key":"1143_CR165","doi-asserted-by":"publisher","first-page":"934","DOI":"10.4049\/jimmunol.1600581","volume":"197","author":"E Yang","year":"2016","unstructured":"Yang E, Singh BK, Paustian AM, Kambayashi T (2016) Diacylglycerol kinase zeta is a target to enhance NK cell function. J Immunol 197:934\u2013941","journal-title":"J Immunol"},{"key":"1143_CR166","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1182\/blood-2008-05-158253","volume":"113","author":"AS Yong","year":"2009","unstructured":"Yong AS, Keyvanfar K, Hensel N, Eniafe R, Savani BN, Berg M, Lundqvist A, Adams S, Sloand EM, Goldman JM, Childs R, Barrett AJ (2009) Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood 113:875\u2013882","journal-title":"Blood"},{"key":"1143_CR167","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.4049\/jimmunol.161.7.3400","volume":"161","author":"T Yoshimoto","year":"1998","unstructured":"Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H, Akira S, Nakanishi K (1998) IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol 161:3400\u20133407","journal-title":"J Immunol"},{"key":"1143_CR168","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cytob.21134","volume":"86","author":"W Zeijlemaker","year":"2014","unstructured":"Zeijlemaker W, Gratama JW, Schuurhuis GJ (2014) Tumor heterogeneity makes AML a \u201cmoving target\u201d for detection of residual disease. Cytometry B 86:3\u201314","journal-title":"Cytometry B"},{"key":"1143_CR169","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1084\/jem.20150792","volume":"212","author":"Z Zhang","year":"2015","unstructured":"Zhang Z, Wu N, Lu Y, Davidson D, Colonna M, Veillette A (2015) DNAM-1 controls NK cell activation via an ITT-like motif. J Exp Med 212:2165\u20132182","journal-title":"J Exp Med"},{"key":"1143_CR170","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3389\/fimmu.2017.00533","volume":"8","author":"C Zhang","year":"2017","unstructured":"Zhang C, Oberoi P, Oelsner S, Waldmann A, Lindner A, Tonn T, Wels WS (2017) Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity. Front Immunol 8:533","journal-title":"Front Immunol"},{"key":"1143_CR171","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","volume":"19","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, Wang Z, Wu Q, Peng H, Wei H, Sun R, Tian Z (2018a) Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol 19:723\u2013732","journal-title":"Nat Immunol"},{"key":"1143_CR172","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.yexcr.2018.09.013","volume":"372","author":"W Zhang","year":"2018","unstructured":"Zhang W, Feng H, Chen Q, Lu X, Ge J (2018b) The functional potency of natural killer cells in response to IL-2\/IL-15\/IL-21 stimulation is limited by a concurrent upregulation of Tim-3 in bladder cancer. Exp Cell Res 372:92\u201398","journal-title":"Exp Cell Res"},{"key":"1143_CR173","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3389\/fimmu.2017.01194","volume":"8","author":"A Zingoni","year":"2017","unstructured":"Zingoni A, Fionda C, Borrelli C, Cippitelli M, Santoni A, Soriani A (2017) Natural killer cell response to chemotherapy-stressed cancer cells: role in tumor immunosurveillance. Front Immunol 8:1194","journal-title":"Front Immunol"},{"key":"1143_CR174","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","volume":"8","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8:59\u201373","journal-title":"Nat Rev Immunol"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-019-01143-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12272-019-01143-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-019-01143-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T18:03:15Z","timestamp":1694714595000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12272-019-01143-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,20]]},"references-count":174,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["1143"],"URL":"https:\/\/doi.org\/10.1007\/s12272-019-01143-y","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,20]]},"assertion":[{"value":"7 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}